DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference.
Key Points:
- DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Patrick Holt, Amarin’s president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference.
- H.C. Wainwright 2nd Annual BioConnect Investor Conference (May 20th, 2024; NYC)
Retrieved on:
Wednesday, April 24, 2024
American Heart,
FDA,
Patient,
HealthyWomen,
University,
Stroke,
Professional corporation,
Risk,
Woman,
Food,
CVD,
Health,
Death,
Fenofibrate,
History,
Prescription,
Science,
CFR,
Commissioner,
Cardiovascular disease,
Clinical trial,
Associate,
Amarin,
Medical director,
Pharmaceutical industry “Despite the many safe, effective, and FDA-approved treatments available on the market with clinically proven reductions of CVD risk, patients are still being treated with fenofibrates off-label.
Key Points:
- “Despite the many safe, effective, and FDA-approved treatments available on the market with clinically proven reductions of CVD risk, patients are still being treated with fenofibrates off-label.
- This results in patients taking a drug proven to have no clinical benefit to reduce CVD risk,” said Nabil Abadir, M.D., Chief Medical Officer at Amarin.
- “This is a significant issue that is risking patient health and should be addressed quickly by the FDA.
- The petition also urges the FDA Commissioner to further clarify the position the agency previously took by removing the statin co-administration from fenofibrate labeling.
DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting (AGM).
Key Points:
- DUBLIN, Ireland and BRIDGEWATER, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting (AGM).
- Importantly, shareholders approved each of the two proposals required for the Company to proceed with its previously announced intent to pursue a share repurchase program of up to $50 million.
- “We thank our shareholders for their engagement and for taking the time to vote on key matters for the Company,” said Odysseas Kostas, M.D.
- We look forward to completing the necessary steps to begin share repurchases as soon as possible.”
Full voting results will be included in an upcoming SEC 8-K filing.
The conference call with management will follow the release of the Company’s first quarter 2024 financial results in the pre-market hours.
Key Points:
- The conference call with management will follow the release of the Company’s first quarter 2024 financial results in the pre-market hours.
- Starting on April 15th at 8:00 am ET, all shareholders are encouraged to submit questions by visiting: https://app.saytechnologies.com/amarin-2024-q1 .
- This Q&A platform will remain open until 48 hours prior to the start of the earnings call.
- Conference Call and Webcast Information:
Access to the live call:
Dial in within the United States: 888-506-0062
Vitamin E,
Plasma,
Rosuvastatin,
Inflammation,
Nitric oxide,
Protein,
EPA,
Angiotensin,
Endothelial dysfunction,
Oxidative stress,
Dietary supplement These findings indicate that the net benefits of a high intensity statin and EPA, compared to statin alone, on expression of detoxification proteins during inflammation may contribute to reduced atherothrombotic risk in outcome trials.
Key Points:
- These findings indicate that the net benefits of a high intensity statin and EPA, compared to statin alone, on expression of detoxification proteins during inflammation may contribute to reduced atherothrombotic risk in outcome trials.
- The beneficial effects of a high intensity statin and EPA on endothelial dysfunction may contribute to reduced atherothrombotic risk in outcome trials.
- Elevated Lp(a) levels are an independent and causal risk factor for cardiovascular (CV) disease with limited treatments available.
- The potent antioxidant actions of EPA may contribute to reduced CV events in REDUCE-IT, including among those subjects with elevated Lp(a).
MB,
TGS,
High,
Science,
CH.B,
Risk,
Research,
American College,
MACE,
Professional corporation,
IPE,
JACC,
Pharmaceutical industry DUBLIN, Ireland and BRIDGEWATER, N.J., April 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted two data presentations at ACC.24 describing the effects of VASCEPA®/VAZKEPA® (icosapent ethyl) on reducing MACE (Major Adverse Cardiovascular Events) in patients with baseline high or low Lipoprotein(a) [Lp(a)] levels, as well as reducing the risk of cardiovascular (CV) events in patients irrespective of baseline LDL-C level. The REDUCE-IT analysis results relating Lp(a) concentrations with CV risk were also published online today in the Journal of the American College of Cardiology (JACC).
Key Points:
- There are no treatments currently approved to reduce residual CV risk on top of contemporary medical therapy in patients with high Lp(a) levels.
- In this subanalysis, there were 7,026 REDUCE-IT patients with baseline Lp(a) data and a median Lp(a) value of 11.6 (Q1-Q3: 5.0-37.4) mg/dL.
- Importantly, the treatment benefit of IPE was evident across subgroups with both high (≥50 mg/dL) and low (
- Limitations are that randomization was not stratified by baseline LDL-C, however, baseline characteristics were similar among the two baseline LDL-C subgroups.
Growth,
Risk,
Patient,
EPO,
European Patent Convention,
Patent,
Family,
Professional corporation,
SPCS,
Triglyceride,
Pharmaceutical industry In addition, the Company recently achieved success defending a separate European VAZKEPA patent from third-party opposition within the EPO.
Key Points:
- In addition, the Company recently achieved success defending a separate European VAZKEPA patent from third-party opposition within the EPO.
- Additional independent patent applications from this family remain pending, which when granted, will further reinforce VAZKEPA’s exclusivity in Europe until April 2039.
- Additionally, in November 2023, Amarin successfully defended a separate patent containing claims covering VAZKEPA in Europe from third-party opposition.
- At the conclusion of that opposition, the EPO found all claims for Amarin’s 2033 VAZKEPA patent to be valid.
MB,
Amarin,
REDUCE,
CH.B,
Risk,
Patient,
SVP,
Research,
American College,
EPA,
Abadir Umar ar-Rida,
MACE,
Professional corporation,
IPE DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology’s Annual Scientific Session & Expo, April 6 – 8, 2024 in Atlanta, GA.
Key Points:
- These data demonstrate the molecule’s impact in reducing patients’ residual cardiovascular event risk across these patient sub-groups regardless of their baseline Lp(a) or LDL-C levels.
- Additionally, the meeting provides an opportunity to highlight further evidence regarding the potential mechanistic activity of EPA in reducing cardiovascular events in at-risk patients."
- “This latest research reaffirms Amarin's commitment to advancing cardiovascular care and should help further advance the medical community’s understanding of the role, the value and the potential mechanism of action of VASCEPA/VAZKEPA to reduce cardiovascular events in at-risk patients globally,” concluded Abadir.
- Featured Amarin-supported abstracts to be presented by international academic collaborators at ACC Scientific Sessions 2024 include:
Retrieved on:
Thursday, February 29, 2024
EDT,
Edding,
Research,
IPE,
Investment,
Telephone,
Share repurchase,
Conference,
Professional corporation,
GAAP,
CVRR,
ROW,
Row,
Cryptocurrency DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter and year ended December 31, 2023 and provided an update on the Company’s operations.
Key Points:
- Net product revenue for the three months ended December 31, 2023 was $70.6 million, compared to $89.5 million in the corresponding period of 2022, a decrease of 21%.
- USA net product revenue was $64.9 million for the three months ended December 31, 2023 compared to $88.0 million in the corresponding period of 2022.
- Cost of goods sold for the three months ended December 31, 2023 was $29.6 million, compared to $26.6 million in the corresponding period of 2022.
- As of December 31, 2023, Amarin reported aggregate cash and investments of $321 million.
Retrieved on:
Thursday, February 15, 2024
Key Points:
- ET.
- The call will include brief remarks on 2023 highlights followed by Q&A.
- The conference call with management will follow the release of the Company’s fourth quarter and full year 2023 financial results in the pre-market hours.
- Conference Call and Webcast Information:
Access to the live call:
Dial in within the United States: 888-506-0062
